A5029284830- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Mechanisms and Therapy
- Chronic Myeloid Leukemia Treatments
- Animal Virus Infections Studies
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Platelet Disorders and Treatments
- Cytokine Signaling Pathways and Interactions
Institute for Myeloma & Bone Cancer Research
2019-2022
Summary Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms, which may potentially include the programmed cell death ligand‐1 (PD‐L1):programmed protein‐1 (PD‐1) axis. This interaction contributes to immunosuppressive bone marrow (BM) microenvironment, ultimately leading reduced effector function. PD‐L1 is overexpressed in MMBM and associated with resistance immune‐based approaches for treating MM. Ruxolitinib (RUX), an inhibitor Janus kinase (JAK) family...
Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum M-protein, serum-free light chain ratio, and bone marrow plasma cell percentage. We investigated whether baseline B-cell maturation antigen (sBCMA) levels predictive progression among 65 SMM. A receiver operating characteristic curve was used to establish...